Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy

PURPOSE: Antiangiogenic therapy is commonly being used for the treatment of glioblastoma. However, the benefits of angiogenesis inhibitors are typically transient and resistance often develops. Determining the mechanism of treatment failure of the VEGF monoclonal antibody bevacizumab for malignant g...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Ji, Piao, Yuji, Henry, Verlene, Tiao, Ningyi, de Groot, John F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741619/
https://www.ncbi.nlm.nih.gov/pubmed/26362401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741619/
https://www.ncbi.nlm.nih.gov/pubmed/26362401

Ejemplares similares